iRhythm Technologies, Inc. (IRTC)
NEUTRALFundamental
50
मूल्य
$123.88
मार्केट कैप
$4.24B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
$825M
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$-14M
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
$35M
कुल इक्विटी
$153M
कुल देनदारियाँ
$867M
Current Ratio
3.85
Interest Coverage
1.89
Debt/EBITDA
-
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$104.17
वर्तमान मूल्य
$123.88
Margin of Safety
-18.9%
Fair Value सीमा
$67.71 - $140.63
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
-
ROE
-29.2%
P/B Ratio
22.20
P/FCF
105.92
Gross Margin
71.5%
ROIC
-2.2%
लाभप्रदता Radar
Value Creation (Economic Moat)
ROIC
-2.2%
WACC
10.9%
ROIC − WACC
-13.1 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental विश्लेषण मानदंड
पास (12)
- EPS shows upward trend
- Price CAGR 15.66%
- Gross Margin 71.5%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 23.0%
- Analyst Consensus 95% Buy
- Earnings Surprise avg 3463.2%
- Net Margin Trend -1.7% vs -14.1%
- Piotroski F-Score 6/9
फेल (10)
- ROIC -2.2%
- P/FCF 105.92
- P/B Ratio 22.20
- Debt/Equity ratio
- Operating Margin -3.0%
- CapEx intensity
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -20.6%
- Share Dilution 2.7%
अनुपलब्ध (5)
- Dividend Payout NaN%
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
मिश्रित संकेत: कुछ क्षेत्रों पर ध्यान देना आवश्यक
Earnings गुणवत्ता
निम्न गुणवत्ता: accounting की जांच करें
शेयर Dilution
नए शेयर जारी कर रही है, स्वामित्व को कम कर रही है
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Quentin S. Blackford | President, CEO & Director | 46 |
| Mr. Daniel G. Wilson | CFO & Principal Financial Officer | 43 |
| Dr. Minang P. Turakhia M.D., M.S. | Chief Medical & Scientific Officer and Executive VP of Advanced Technologies | 51 |
| Mr. Patrick Michael Murphy J.D. | Chief Business & Legal Officer | 46 |
| Mr. Chad M. Patterson | Chief Commercial and Product Officer | 43 |
| Mr. Mervin Smith | Executive Vice President of Business Operations | 50 |
| Mr. Marc Rosenbaum | Senior VP of Finance & Chief Accounting Officer | 52 |
| Mr. Brian Lawrence | Executive VP & CTO | 55 |
| Ms. Lisa Pecora | Senior Vice President of Finance & Investor Relations | - |
| Mr. Sean Clinton Freeman | Executive Vice President of Strategy & Corporate Development | 49 |
Audit जोखिम
9
बोर्ड जोखिम
5
मुआवजा जोखिम
3
शेयरधारक अधिकार जोखिम
7
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for IRTC, sourced from Markets Gazette.
- 6/16/2026NEGATIVEiRhythm Investigates Cyber Incident After Hackers Claim Access To Sensitive Data
iRhythm Technologies is investigating a cybersecurity incident where hackers claim to have accessed sensitive patient and proprietary data. The breach reportedly occurred via third-party applications. While the company states it does not foresee a material impact on its operations or finances, any data breach involving patient information can lead to regulatory scrutiny, reputational damage, and potential legal liabilities. Investors will monitor the situation closely for any further developments or undisclosed consequences that could affect the company's long-term prospects and stock valuation.
via Markets Gazette